Nangibotide
LQEEDAGEYGCM-amide
Description
Application Data
Description
-
(TREM)-1 antagonist peptide derived from residues 94 to 105 of TREM-like transcript-1 (TLT-1).
Application Data
-
Data Sheet Material Safety Data Sheet (MSDS)Catalogue number crb1001271 Molecular Weight 1342.5 Sequence (one letter code) LQEEDAGEYGCM-amide
Sequence (three letter code) H-Leu-Gln-Glu-Glu-Asp-Ala-Gly-Glu-Tyr-Gly-Cys-Met-NH2
Aliase LR12 Purity >95% Storage -20°C References Derive et al (2013) Effects of a TREM-Like Transcript 1–Derived Peptide During Hypodynamic Septic Shock in Pigs. Shock 39(2) 176 PMID: 23324887
Derive et al (2014) Attenuation of Responses to Endotoxin by the Triggering Receptor Expressed on Myeloid Cells-1 Inhibitor LR12 in Nonhuman Primate. Anesthesiology 120(4) 935 PMID: 24270127
Derive et al (2012) Soluble Trem-like Transcript-1 Regulates Leukocyte Activation and Controls Microbial Sepsis. J. Immunol. 188(11) 5585 PMID: 22551551
Manufactured in: United Kingdom Nangibotide, also referred as LR12, is an antagonist of triggering receptor expressed on myeloid cells (TREM)-1, and was derived from residues 94 to 105 of TREM-like transcript-1 (TLT-1).
TREM-1 plays a crucial role in the onset of sepsis by amplifying the host immune response. TLT-1– and TLT-1–derived peptides therefore exhibit anti-inflammatory properties by dampening TREM-1 signalling. LR12 blocks TREM-1 by binding to the TREM-1 ligand and provides protective effects during sepsis such as inhibiting hyper-responsiveness, organ damage, and death, without causing deleterious effects. The protective effects of modulating TREM-1 signalling are also evident in other models of inflammation such as: pancreatitis; haemorrhagic shock; inflammatory bowel diseases and inflammatory arthritis.